N/A UNCHANGED Last Price Updated: Add to My Watchlist
All news about
SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Cell Therapeutics, Inc. Regarding Possible Breaches of Fiduciary Duty
May 29, 2014
Top Gainers on the Move -- Research on Aeropostale, FirstEnergy, Cell Therapeutics, and Dyax
May 27, 2014
Thursday's ETF Movers: XBI, EWD
June 05, 2014
In trading on Thursday, the SPDR S&P Biotech ETF (XBI) is outperforming other ETFs, up about 2.8% on the day. Components of that ETF showing particular strength include shares of Celldex Therapeutics...
From ETF Channel
Markets advance as existing home sales rise
May 22, 2014
The market advanced during the midday with the Dow gaining 18 points to 16,551 as existing home sales rose. Nasdaq climbed 23 points to 4,154.
Tags Market News
Interesting CTIC Put And Call Options For July 19th
May 20, 2014
Investors in Cell Therapeutics, Inc. (CTIC) saw new options become available this week, for the July 19th expiration..
Technical Coverage on Biotech Stocks -- Research on Celgene, Cell Therapeutics, Geron, and BioMarin Pharma
May 06, 2014
- Reports Net Product Sales Growth for PIXUVRI® Following Positive Reimbursement Decisions in Key E.U. Countries -
PIXUVRI® Launched In UK For Adult Patients With Multiply Relapsed Or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
April 28, 2014
Biotech Stocks Technical Data -- Research on Cell Therapeutics, Vanda Pharma, Celldex Therapeutics, and Synta Pharma
April 10, 2014
First Week of CTIC May 17th Options Trading
March 26, 2014
Investors in Cell Therapeutics, Inc. (CTIC) saw new options begin trading this week, for the May 17th expiration..
Insider Trading Research -- Alerts for Ariad Pharmaceuticals, Cell Therapeutics, Staples, Sirius XM, Facebook, and Bank of America
March 25, 2014
Stock to Watch: Cell Therapeutics Down 5.5% (CTIC)
March 24, 2014
Initiation of Clinical Trials, Completed Acquisitions, Financial Results, and Earnings Release Schedules - Analyst Notes on Cell Therapeutics, Intrexon, Chimerix, Receptos, and Revance Therapeutics
March 18, 2014
Lightning Round: Kate Spade, Zulily & More
March 17, 2014
Are you ready skeedaddy???!!! It's time for the Lightning Round. Cramer makes the call on viewer favorites.
From CNBC.com News
Investor-Edge.com Most Active Equities Watch List: Cell Therapeutics, Yandex, Himax Technologies, and CytRx
March 14, 2014
Is It Too Late to Buy the Rally in Small Caps?
March 06, 2014
Moving up: Bazaarvoice (NASDAQ: BV) - up 8% - Reports Q3 EPS of $(0.04) vs $(0.06) est; revenue of $48.0M vs $46.57M est. Smith & ...
- 2014 Priorities: Complete and Report Top-line Results of First Pacritinib Phase 3 and Drive EU Sales of PIXUVRI -
Earnings Scheduled For March 4, 2014
March 03, 2014
AutoZone (NYSE: AZO) is expected to report its Q2 earnings at $5.55 per share on revenue of $1.97 billion. The E. W. Scripps Company ...
CTI Opens Enrollment for PERSIST-2 Phase 3 Trial of Pacritinib for Patients with Myelofibrosis Who Have Low Platelet Counts
March 02, 2014
Mornings Movers for Feb. 27, 2014: PEIX, JCP, SYMX, CIE, SHLD, BBY Higher, INO, NDLS, HK, CY, DYAX Lower
February 27, 2014
Moving up: Pacific Ethanol (NASDAQ: PEIX ) - up 29% - reports Q4 EPS of $0.54 vs $(0.04) analyst estimates. Revenue came in at $215.30M. JC Penney (NYSE: JCP ) - up 22% - EPS of $0.11 vs $(0.76) Est;...
NICE Publishes Final Guidance on PIXUVRI® (pixantrone)
February 26, 2014
- Published Final Guidance Recommending PIXUVRI as Cost Effective and Provides Patients with Aggressive B-cell Non-Hodgkin Lymphoma (NHL) Greater Access to Only Approved Therapy -